Table II.

Prevalence of the maternal health conditions during pregnancy in the case-control study of acute leukemia in children with Down syndrome.

	No. of controls (%)	No. of all cases (%)	No. of ALL cases (%)	No. of AML cases (%)
Hypertension**
No	153 (88.4)	147 (93.0)	91 (93.8)	56 (91.8)
Yes	20 (11.6)	11 (7.0)	6 (6.2)	5 (8.2)
Preeclampsia or Toxemia
No	164 (95.3)	154 (98.1)	94 (96.9)	60 (100.0)
Yes	8 (4.7)	3 (1.9)	3 (3.1)	0 (0.0)
Heart Disease
No	168 (97.1)	154 (97.5)	94 (96.9)	60 (98.4)
Yes	5 (2.9)	4 (2.5)	3 (3.1)	1 (1.6)
Urinary tract or bladder infection**
No	147 (85.0)	137 (86.7)	85 (87.6)	52 (85.2)
Yes	26 (15.0)	21 (13.3)	12 (12.4)	9 (14.8)
Kidney infection
No	170 (98.8)	157 (99.4)	96 (99.0)	61 (100.0)
Yes	2 (1.2)	1 (0.6)	1 (1.0)	0 (0.0)
Threatened miscarriage
No	157 (91.3)	144 (92.3)	89 (91.8)	55 (93.2)
Yes	15 (8.7)	12 (7.7)	8 (8.2)	4 (6.8)
Vaginal bleeding**
No	130 (75.1)	129 (81.6)	78 (80.4)	51 (83.6)
Yes	43 (24.9)	29 (18.4)	19 (19.6)	10 (16.4)
Genital warts
No	172 (99.4)	154 (98.7)	96 (99.0)	58 (98.3)
Yes	1 (0.6)	2 (1.8)	1 (1.0)	1 (1.7)
Gestational diabetes**
No	154 (89.0)	142 (89.9)	87 (89.7)	55 (90.2)
Yes	19 (11.0)	16 (10.1)	10 (10.3)	6 (9.8)
Insulin use during pregnancy
No	168 (97.1)	154 (98.1)	95 (97.9)	59 (98.3)
Yes	5 (2.9)	3 (1.9)	2 (2.1)	1 (1.7)
Thyroid medication use in pregnancy
No	165 (95.4)	150 (95.5)	94 (96.9)	56 (93.3)
Yes	8 (4.6)	7 (4.5)	3 (3.1)	4 (6.7)
Steroid/Immunosuppressant use in
pregnancy
No	165 (95.4)	151 (95.6)	92 (94.8)	59 (96.7)
Yes	8 (4.6)	7 (4.4)	5 (5.2)	2 (3.3)
Amniocentesis**
No	154 (89.0)	132 (83.5)	88 (90.7)	44 (72.1)
Yes	19 (11.0)	26 (16.5)	9 (9.3)	17 (27.9)
Chorionic Villus Sampling
No	169 (99.4)	154 (98.1)	95 (97.9)	59 (98.3)
Yes	1 (0.6)	3 (1.9)	2 (2.1)	1 (1.7)

^**At least 5 cases of both ALL and AML and 5 controls reported the event.